[
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges",
    "summary": "Pfizer (NYSE:PFE) recently ended its strategic collaboration with Acepodia and is facing legal challenges related to Depo-Provera, reflecting significant changes that provide a backdrop of strategic reorientation and scrutiny. During a period of mixed market activity, as major indexes showed slight fluctuations amidst Nvidia's strong earnings and trade policy adjustments, Pfizer's performance remained stable, aligned with broader market trends. Although the company's stock move was not...",
    "url": "https://finnhub.io/api/news?id=1c7bd4e55d54e00b85b1d02c2302fd5fbc55b4706fda78efa8107f26eb50568d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748540492,
      "headline": "Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges",
      "id": 134844495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) recently ended its strategic collaboration with Acepodia and is facing legal challenges related to Depo-Provera, reflecting significant changes that provide a backdrop of strategic reorientation and scrutiny. During a period of mixed market activity, as major indexes showed slight fluctuations amidst Nvidia's strong earnings and trade policy adjustments, Pfizer's performance remained stable, aligned with broader market trends. Although the company's stock move was not...",
      "url": "https://finnhub.io/api/news?id=1c7bd4e55d54e00b85b1d02c2302fd5fbc55b4706fda78efa8107f26eb50568d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=71b0590195d7ee2575f0006280875f0039a89ffb3d0bc1f119d8f9bb30f85fd1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748536560,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 134898217,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=71b0590195d7ee2575f0006280875f0039a89ffb3d0bc1f119d8f9bb30f85fd1"
    }
  },
  {
    "ts": null,
    "headline": "PFE or LLY: Which Is the Better Value Stock Right Now?",
    "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=b7e79bd5aba226b382378eba551109b75588fbe4c911bf671ecbd6e15170cd44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748533208,
      "headline": "PFE or LLY: Which Is the Better Value Stock Right Now?",
      "id": 134844496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=b7e79bd5aba226b382378eba551109b75588fbe4c911bf671ecbd6e15170cd44"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound?",
    "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=85bcd28c86f8cde4a07fb72ea896740db96a7e39b8f5190cd8ab8227c742e3d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748532656,
      "headline": "Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound?",
      "id": 134844497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=85bcd28c86f8cde4a07fb72ea896740db96a7e39b8f5190cd8ab8227c742e3d8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Arvinas gamble to shift breast cancer treatment paradigm",
    "summary": "Vepdegestrant is an oral proteolysis-targeting chimera ER degrader which slows tumour growth.",
    "url": "https://finnhub.io/api/news?id=8e959ce31ce4b3b783acc505ee29afd644821747b32e7cdb06180e44b1903df7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748528943,
      "headline": "Pfizer and Arvinas gamble to shift breast cancer treatment paradigm",
      "id": 134812347,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vepdegestrant is an oral proteolysis-targeting chimera ER degrader which slows tumour growth.",
      "url": "https://finnhub.io/api/news?id=8e959ce31ce4b3b783acc505ee29afd644821747b32e7cdb06180e44b1903df7"
    }
  },
  {
    "ts": null,
    "headline": "Intellia: Heart Disease Safety Setback Triggers Selloff - Caution Advised",
    "summary": "Intellia: Heart Disease Safety Setback Triggers Selloff - Caution Advised",
    "url": "https://finnhub.io/api/news?id=7c3dc274d59fe51498aa255157423d647b8db62d528dac9aae055ee7f328b241",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748528710,
      "headline": "Intellia: Heart Disease Safety Setback Triggers Selloff - Caution Advised",
      "id": 134837621,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7c3dc274d59fe51498aa255157423d647b8db62d528dac9aae055ee7f328b241"
    }
  },
  {
    "ts": null,
    "headline": "Are Investors Undervaluing Pfizer (PFE) Right Now?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=513be05644771ac6618bd26c0a25e11526f4db10ee50c6aa77fc57b21694252d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748526013,
      "headline": "Are Investors Undervaluing Pfizer (PFE) Right Now?",
      "id": 134844499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=513be05644771ac6618bd26c0a25e11526f4db10ee50c6aa77fc57b21694252d"
    }
  },
  {
    "ts": null,
    "headline": "5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio",
    "summary": "The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.",
    "url": "https://finnhub.io/api/news?id=f8eb9a698d0255b37260ead6dd3d1508693edeb8ff763c94fa1b9c6113a474c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748523900,
      "headline": "5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio",
      "id": 134812349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.",
      "url": "https://finnhub.io/api/news?id=f8eb9a698d0255b37260ead6dd3d1508693edeb8ff763c94fa1b9c6113a474c7"
    }
  },
  {
    "ts": null,
    "headline": "Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field",
    "summary": "Vutrisiran, recently FDA-approved for ATTR-CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.",
    "url": "https://finnhub.io/api/news?id=17c79521e4181b84d5058d498e1d548f99f9d6039ffbe48e8747f5a80fda9012",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748511580,
      "headline": "Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field",
      "id": 134808389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2113450059/image_2113450059.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Vutrisiran, recently FDA-approved for ATTR-CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.",
      "url": "https://finnhub.io/api/news?id=17c79521e4181b84d5058d498e1d548f99f9d6039ffbe48e8747f5a80fda9012"
    }
  },
  {
    "ts": null,
    "headline": "PFIZER INC : Berenberg reaffirms its Neutral rating",
    "summary": "Initially Neutral on the company, Berenberg's analyst Kerry Holford maintained his recommendation. The target price is reduced from USD 28 to USD 25.",
    "url": "https://finnhub.io/api/news?id=aa577ad0030952f1fa2946cf8b1f106143197e0f8f62b4ff16b8dd393938d2e5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748502436,
      "headline": "PFIZER INC : Berenberg reaffirms its Neutral rating",
      "id": 134801570,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Initially Neutral on the company, Berenberg's analyst Kerry Holford maintained his recommendation. The target price is reduced from USD 28 to USD 25.",
      "url": "https://finnhub.io/api/news?id=aa577ad0030952f1fa2946cf8b1f106143197e0f8f62b4ff16b8dd393938d2e5"
    }
  },
  {
    "ts": null,
    "headline": "U.S. VCs Race to Tap China’s Biotech Innovation",
    "summary": "U.S. VCs Race to Tap China’s Biotech Innovation",
    "url": "https://finnhub.io/api/news?id=30a066ae8988e66eec7e8f2e3bd3ae22ab101cff4e4ea0e9dce43670c35f7f0d",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748498400,
      "headline": "U.S. VCs Race to Tap China’s Biotech Innovation",
      "id": 134942769,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "U.S. VCs Race to Tap China’s Biotech Innovation",
      "url": "https://finnhub.io/api/news?id=30a066ae8988e66eec7e8f2e3bd3ae22ab101cff4e4ea0e9dce43670c35f7f0d"
    }
  }
]